Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Eric Lefkofsky

Tempus AI, Inc. Class A Common Stock

WELL Health.ai develops and invests in AI-enabled tools and technologies for healthcare providers, aiming to positively impact health outcomes.

WELL Health.ai

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

MedTech Engine provides information and resources related to medical breakthroughs, health research, personal health, and medical technology. They cover topics such as chronic illness management, medical procedures, and healthcare industry solutions.

MedTech Engine

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. 

Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. 

For more information, visit tempus.com and follow us on Twitter (@TempusLabs). 

Tempus AI

Our founder and CEO, Eric Lefkofky, joins mHUB for next week's HardTech Summit to discuss his path to #AI enabled healthcare. Register here: https://tempus.co/4c2W6Q2 

Dr. Ezra Cohen’s personal passion for taking care of cancer patients led him from decades of clinical care and research to Tempus as our Chief Medical Officer of Oncology. In our #TempusWhy series, Dr. Cohen shares how our work at Tempus fuels his unwavering commitment and determination to advancing cancer care. 

Hear more: 

Physicians like Dr. James and their care teams seamlessly use Tempus One to make informed patient treatment decisions through convenient functionalities that deliver insights on patient’s full clinical and molecular profile. By improving clinical workflows, One can allow more time for teams to focus on patient care. Learn more about Tempus One: https://tempus.co/42ZDYT4 

We’re looking forward to being on-site this week at the Liquid Biopsy for Precision Oncology Summit. Attend Adam Morabito’s presentation on how emerging technologies and multi-modal data have unlocked novel use cases for tumor-naïve liquid biopsies. Learn more: https://tempus.co/4bIlHha 

We’re #NowHiring for a Territory Sales Executive to join our team in North Atlanta. This position will drive new opportunities with major US cancer centers, clinics, and oncology practices. Join our growing sales team by applying here: https://bit.ly/3T6HkjX #atljobs 

Metric
Company Name	Tempus AI, Inc. Class A Common Stock	WELL Health.ai	DVLP	MedTech Engine
Symbol	TEM
MSH ID	COM:TEMPUS	AI:WELLHEALTH	COM:DVLPMEDICINES	COM:MEDTECHENGINE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare	Healthcare Technology	Pharmaceuticals	Health Information Services
Country	US	CA	US	US
Stage		Seed
Employee Count
Website	tempus.com	wellhealth.ai	dvlpmedicines.com	medtechengine.com
LinkedIn	tempusai	wellhealthtechnologiescorp	dvlpmedicines	medtechengine
Founders

Metric
Market Cap	5.77B
Enterprise Value
Monthly Web Traffic	158.50K	1	133
Web Traffic Growth	2.47	-0.99	-0.55
Valuation
Raised Capital		1.20M

Metric
Revenue	531.82M
Revenue (LTM)
Revenue (NTM)
Gross Profit	286.18M
EBITDA	-133.33M
Operating Income	-196.08M
Net Income	-214.12M
EPS	-1.34
Diluted EPS	-1.34
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54
Operating Profit Margin	-0.35
EBITDA Margin	-0.25
Net Profit Margin	-0.40
Return on Equity	0.99
Return on Assets	-0.48
Return on Capital Employed	-0.75

TEM

COM:TEMPUS

Tempus

Last Close

52.48

22/11 21:00

Market Cap

5.77B

Beta: -

Volume Today

1.19M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-29.38
P/B Ratio	-19.42
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	17.85
EV Multiple	-9.18

Metric
Days Sales Outstanding	70.01
Days Payables Outstanding	61.77
Days Inventory Outstanding	42.30
Operating Cycle	113.57
Cash Conversion Cycle	77.48
Asset Turnover	1.20

Metric
Operating Cash Flow	-214.34M
Free Cash Flow	-248.95M
Cash Flow to Debt	-0.55
Operating Cash Flow/Sales	-0.44
Free Cash Flow Yield	-0.04

Metric
Cash & Equivalents	165.77M
Accounts Receivable	-7.35M
Inventory	28.84M
Goodwill	73.35M
Debt to Capitalization	4.01
Debt to Assets	0.96
Current Ratio	1.23
Quick Ratio	3.52

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.34
SG&A to Revenue